SEC Tracker
Get the app

Arcutis Biotherapeutics ARQT

Arcutis Biotherapeutics reported $143.92 million in revenue for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $143.92 million for the three months ended Sep 30, 2026
  2. Net income: $8.8 million for the three months ended Sep 30, 2026
  3. Diluted EPS: $0.06 for the three months ended Sep 30, 2026
  4. Cash and equivalents: $33.37 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Arcutis Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  2. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  3. Arrowhead Pharmaceuticals ARWR public float $1.4B, Mar 31, 2025, over 18 months old
  4. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025